Frontier Medicines Secures $67 Million Series A Financing to Advance Novel Therapies Targeting 'Undruggable' Protein Sites

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 25, U.S. local time, biopharmaceutical company Frontier Medicines completed a $67 million Series A financing round. The funds from this round will be used to support the company's research and development of drugs targeting multiple protein targets.

It is reported that this round of financing was led by Deerfield, DROIA Oncology Ventures, and MPM Capital, with participation from RA Capital Management and other investors.

Frontier Medicines, founded in 2018 and headquartered in California, USA, is a clinical-stage biopharmaceutical company.

To date, approximately 90% of human proteins are considered undruggable by small-molecule therapeutics due to the absence of known binding sites on their surfaces, thereby preventing most drugs from engaging these proteins to treat diseases. However, Frontier Medicines posits that proteins undergo conformational changes during dynamic motion, creating transient pockets that can serve as druggable targets.

By leveraging chemoproteomics technologies, Frontier Medicines has discovered that these transient targets can traverse various human cell membranes and bind with drugs to treat diseases. This breakthrough enables the therapeutic intervention of multiple viral proteins, which were previously considered "undruggable" by the medical community, thereby making it possible to cure a variety of intractable diseases.

Daniel K. Nomura, Co-Founder of Frontier Medicines, stated, “Our platform covers a substantial portion of the human proteome, including proteins traditionally considered undruggable by the medical community. We will leverage computational technologies to continuously expand our covalent compound library and accelerate the development of novel protein degradation therapies for cancers that currently lack effective treatments. Our company’s platform will provide the data support necessary for advancing our protein-targeted therapeutic technologies.”

Deerfield, founded in New York, USA in 1994, is an investment management company dedicated to advancing the healthcare industry through strategic investments. The firm manages over $8 billion in assets and has completed 79 investments to date.

DROIA Oncology Ventures, established in 2011 and headquartered in Luxembourg, is a venture capital firm specializing in investments in startups within the oncology therapeutics sector. To date, it has completed eight investments.

MPM Capital, established in 1996 and headquartered in Massachusetts, USA, is a venture capital firm dedicated to providing growth capital to early- and late-stage companies. With a primary focus on the healthcare sector, the firm has completed 203 investments to date. In addition to financial support, MPM Capital deploys specialized teams to assist portfolio companies in technology development and scientific management.

RA Capital Management, founded in 2001 and headquartered in Massachusetts, USA, is a venture capital firm focused on investing in companies in the early and late stages of development within the life sciences and drug development sectors. It has completed 111 investments to date.

(Compiled by Liu Yujing)